ArticleBiochimica et biophysica acta2013
The human secretome atlas initiative: implications in health and disease conditions.
Article in Biochimica et biophysica acta, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Article
- Article
- Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics.Biomarker research · 2024Review
- A Nucleic Acid-Based LYTAC Plus Platform to Simultaneously Mediate Disease-Driven Protein Downregulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Sorting secretory proteins.eLife · 2023Article
- IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins.Molecules (Basel, Switzerland) · 2023Article
- Glial cell proteome using targeted quantitative methods for potential multi-diagnostic biomarkers.Clinical proteomics · 2023Article
- Beyond canonical PROTAC: biological targeted protein degradation (bioTPD).Biomaterials research · 2023Review
- Review
- Emerging Role of Neuron-Glia in Neurological Disorders: At a Glance.Oxidative medicine and cellular longevity · 2022Review
- Article
- Genes, environment, and developmental timing: New insights from translational approaches to understand early origins of respiratory diseases.Pediatric pulmonology · 2021Article
- Protein degradation technology: a strategic paradigm shift in drug discovery.Journal of hematology & oncology · 2021Review
- Systemic sclerosis biomarkers detection in the secretome of TGFβ1-activated primary human lung fibroblasts.Journal of proteomics · 2021Article
- The cancer cell secretome drives cooperative manipulation of the tumour microenvironment to accelerate tumourigenesis.Faculty reviews · 2021Review
- Article
- Secretome-Based Screening in Target Discovery.SLAS discovery : advancing life sciences R & D · 2020Review
- COMBSecretomics: A pragmatic methodological framework for higher-order drug combination analysis using secretomics.PloS one · 2020Article
- Impaired Airway Epithelial Barrier Integrity in Response toFrontiers in immunology · 2020Article
- The neuro-glial coagulonome: the thrombin receptor and coagulation pathways as major players in neurological diseases.Neural regeneration research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Proteomic analysis of human body fluids is highly challenging, therefore many researchers are redirecting efforts toward secretome profiling. The goal is to define potential biomarkers and therapeutic targets in the secretome that can be traced back in accessible human body fluids. However, currently there is a lack of secretome profiles of normal human primary cells making it difficult to assess the biological meaning of current findings. In this study we sought to establish secretome profiles of human primary cells obtained from healthy donors with the goal of building a human secretome atlas. Such an atlas can be used as a reference for discovery of potential disease associated biomarkers and eventually novel therapeutic targets. As a preliminary study, secretome profiles were established for six different types of human primary cell cultures and checked for overlaps with the three major human body fluids including plasma, cerebrospinal fluid and urine. About 67% of the 1054 identified proteins in the secretome of these primary cells occurred in at least one body fluid. Furthermore, comparison of the secretome profiles of two human glioblastoma cell lines to this new human secretome atlas enabled unambiguous identification of potential brain tumor biomarkers. These biomarkers can be easily monitored in different body fluids using stable isotope labeled standard proteins. The long term goal of this study is to establish a comprehensive online human secretome atlas for future use as a reference for any disease related secretome study. This article is part of a Special Issue entitled: An Updated Secretome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.